Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Commodore Capital reported a sale of 850,000 shares of Nuvalent (NUVL +1.46%) in its latest SEC filing dated February 17, 2026, with the estimated transaction value at $83.81 million based on quarterly average pricing.

What happened

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Commodore Capital sold 850,000 shares of Nuvalent during the fourth quarter of 2025. The estimated value of these sales was $83.81 million based on the average closing price for the period. The stake’s quarter-end value declined by $65.75 million, a figure that includes the impact of both trading and price changes.

What else to know

• This was a net sale, reducing Nuvalent’s share of 13F AUM from 9.26% before the quarter to 3.68% after.
• Top five holdings after the filing:
  • NASDAQ:RLAY: $143.82 million (9.57% of AUM)
  • NASDAQ:ALKS: $99.33 million (6.61% of AUM)
  • NASDAQ:TYRA: $88.73 million (5.91% of AUM)
  • NASDAQ:XENE: $80.68 million (5.37% of AUM)
  • NASDAQ:SYRE: $78.24 million (5.21% of AUM)
• As of February 17, 2026, Nuvalent shares were priced at $102.24, up 29% over the previous year and well outperforming the S&P 500’s roughly 13% gain in the same period.

Company overview

Company snapshot

• Nuvalent develops targeted therapies for cancer, with lead product candidates NVL-520 (a ROS1-selective inhibitor) and NVL-655 (an ALK-selective inhibitor) currently in early-stage clinical trials.
• The company operates a clinical-stage biopharmaceutical model, investing in research and development to advance novel oncology treatments, with future revenue potential dependent on successful regulatory approval and commercialization.
• Nuvalent targets oncologists and healthcare providers treating patients with cancers driven by specific genetic mutations, focusing on unmet needs in the oncology market.

Nuvalent, Inc. is a Cambridge-based biotechnology company specializing in the discovery and development of precision therapies for cancer. The company leverages its expertise in kinase inhibitor design to address resistance and central nervous system challenges in targeted oncology. With a pipeline of differentiated clinical candidates, Nuvalent aims to deliver transformative therapies for patients with limited treatment options.

What this transaction means for investors

Cutting Nuvalent from 9% of assets to 4% in a single quarter looks like a statement about risk tolerance after a run.

To be clear, however, Nuvalent is not a broken story. The company ended 2025 with roughly $1.4 billion in cash and expects runway into 2029. The FDA has accepted its NDA for zidesamtinib in ROS1 positive non small cell lung cancer, with a PDUFA date set for September 18, and an ALK program filing planned in the first half of this year. Those are tangible catalysts.

Shares sit above $100 after a 29% one year gain. And for a fund that concentrates in early stage names like Relay, Tyra and Xene, trimming into strength can be about capital recycling, not lost faith.

Ultimately, long-term investors should focus on two questions. Does Nuvalent convert regulatory momentum into commercial execution in 2026. And can its pipeline sustain growth beyond the first launch. If the answer is yes, volatility around ownership changes may end up looking like noise, not signal.